pacemaker

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | Jenavalve Trilogy System: Valve for Severe Aortic Regurgitation

Though the different percutaneous valves have been designed and authorized for aortic stenosis with tricuspid valve, they have often been used to treat aortic regurgitation as an off-label indication. The Jenavalve Trilogy valve has recently received the CE Mark for aortic regurgitation and aortic stenosis.&nbsp; This study included 45 patients with severe AR. Primary end<a href="https://solaci.org/en/2022/05/23/europcr-2022-jenavalve-trilogy-system-valve-for-severe-aortic-regurgitation/" title="Read more" >...</a>

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | LYTEN Trial: V-in-V in Small Annuli

TAVR is a valid alternative to treat failed surgical bioprosthetic valves, but one of its biggest challenges is patients with a small annulus. When using self-expanding valves, supra-annular implantation is recommended. However, at present, we only have retrospective, observational studies, not large enough.&nbsp; The LYTEN Trial is a randomized study in patients presenting failed bioprosthetic<a href="https://solaci.org/en/2022/05/23/europcr-2022-lyten-trial-v-in-v-in-small-annuli/" title="Read more" >...</a>

estos son los artículos más leídos sobre tavi

Same-Day Discharger After TAVR: Are We There Yet?

Same-day discharge (SDD) has been shown to be effective in angioplasties and some peripheral procedures, but the pandemic—because of the burden it caused on the healthcare system—has forced the optimization of hospitalization times for other pathologies and procedures. This strategy is yet to be tested in transcatheter aortic valve replacement (TAVR) due to the possible<a href="https://solaci.org/en/2022/04/01/same-day-discharger-after-tavr-are-we-there-yet/" title="Read more" >...</a>

Tavi en pacientes com bajo flujo, bajo gradiente clásico

TRICENTO: Promising Results for Severe Tricuspid Valve Regurgitation

Difficult to treat, tricuspid valve failure poses great medical challenge. In addition, the mortality rate of surgical treatment these days is not exactly low, involving high risk, which often takes this alternative off the table.&nbsp;&nbsp; Several percutaneous devices have been developed to treat this disease, the most popular being edge-to-edge devices.&nbsp; The TRICENTO has an<a href="https://solaci.org/en/2022/03/25/tricento-promising-results-for-severe-tricuspid-valve-regurgitation/" title="Read more" >...</a>

La revascularización incompleta se asocia a mortalidad en el TAVI

Low Risk Patients: TAVR with Self-Expanding Valves Offers Similar Outcomes to Surgery Based on a Bayesian Analysis?

When compared against surgical valve replacement (SAVR) transcatheter aortic valve replacement (TAVR) has shown benefits across different risk groups, not only in events as death and stroke, but also in quality of life (especially in the first months post procedure) and improved symptoms.&nbsp; However, a catch-up phenomenon was observed in low-risk patients between the first<a href="https://solaci.org/en/2022/03/17/low-risk-patients-tavr-with-self-expanding-valves-offers-similar-outcomes-to-surgery-based-on-a-bayesian-analysis/" title="Read more" >...</a>

¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

Are Self-Expandable Valves a Valid Option in Bicuspids?

Bicuspid Aortic Valves (VAV) are challenging for TAVR given its anatomical characteristics and the important presence of calcification. However, current data are promising.&nbsp; Even though traditionally excluded from the larger randomized studies, self-expandable valves appear to have similar evolution to tricuspid aortic valves (TAV) with severe stenosis.&nbsp; Researchers looked at the Low-Risk Bicuspid Study and<a href="https://solaci.org/en/2022/03/16/are-self-expandable-valves-a-valid-option-in-bicuspids/" title="Read more" >...</a>

Sangrado y mortalidad en el reemplazo valvular aórtico por catéter

Are Expandable-Balloon Valves an Option for the Bicuspid Valve in Low-Risk Patients?

Bicuspid aortic valve malformation is the most frequent cardiac malformation (about 1%), and a significant percentage of these cases generate severe aortic stenosis. As we know, transcatheter aortic valve replacement (TAVR) has been developed for tricuspid valves, which are studied in the most important randomized trials for high-, medium-, and low-risk patients. While current information<a href="https://solaci.org/en/2022/03/16/are-expandable-balloon-valves-an-option-for-the-bicuspid-valve-in-low-risk-patients/" title="Read more" >...</a>

¿Fin de la discusión sobre el impacto del marcapaso post TAVI?

Is Cusp Overlapping Projection the New Self-Expandable Valve Implantation Technique?

In Europe and the US, aortic stenosis is the most frequent cause of valve intervention, both surgical and percutaneous, and, as we all know, TAVR has made great progress in this regard.&nbsp; However, this technique has an Achilles heel when it comes to self-expandable valves: definite pacemaker implantation rate is 3 to 4 times higher<a href="https://solaci.org/en/2022/03/11/is-cusp-overlapping-projection-the-new-self-expandable-valve-implantation-technique/" title="Read more" >...</a>

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVI

HYDRA CE | New Models for TAVR Development

The Hydra CE has shown favorable one year efficacy for the new transcatheter aortic valve model, with large effective orifice and low transvalvular gradient associated to an acceptable complications rate.&nbsp; With this study, the Hydra will obtain the CE mark and go after FDA approval (just as all new devices).&nbsp; This study looked at safety<a href="https://solaci.org/en/2022/01/19/hydra-ce-new-models-for-tavr-development/" title="Read more" >...</a>

Monitoreo Post Angioplastia

Minimizing One of Our Major Procedures to a Minimum

In some cases, full atrioventricular (AV) block occurs beyond two days after transcatheter aortic valve replacement (TAVR). This highlights the usefulness of extending monitoring after discharge, particularly in patients who tolerated the procedure well, but meet high-risk criteria. We have made great progress regarding conduction disorders in TAVR, especially after the publication of the consensus<a href="https://solaci.org/en/2022/01/13/minimizing-one-of-our-major-procedures-to-a-minimum/" title="Read more" >...</a>

Top